as 05-09-2025 3:41pm EST
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Founded: | 1988 | Country: | United States |
Employees: | N/A | City: | TARRYTOWN |
Market Cap: | 63.4B | IPO Year: | 1991 |
Target Price: | $907.39 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Buy | Number of Analysts: | 23 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 39.43 | EPS Growth: | 16.49 |
52 Week Low/High: | $520.50 - $1211.20 | Next Earning Date: | 04-29-2025 |
Revenue: | $14,085,700,000 | Revenue Growth: | 7.52% |
Revenue Growth (this year): | 2.38% | Revenue Growth (next year): | 7.65% |
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
StockStory
15 hours ago
Insider Monkey
a day ago
Insider Monkey
2 days ago
Zacks
7 days ago
Insider Monkey
8 days ago
Simply Wall St.
8 days ago
TipRanks
8 days ago
GlobeNewswire
8 days ago
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.